InvestSMART

Proteomics International Laboratories Ltd (ASX: PIQ) - Announcements

Current share price for PIQ : $0.175 0.01 (5.41%)+

ASX company news and announcements for Proteomics International Laboratories Ltd (PIQ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Proteomics International Laboratories Ltd (PIQ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Proteomics International Laboratories Ltd (PIQ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Proteomics International Laboratories Ltd (PIQ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$29 Completion of Entitlement Issue and Shortfall notice 14 Oct 2015 6:00PM $0.240 $0.175 fallen by 27.08%
$29 Corporate Governance Statement and Appendix 4G 1 Oct 2015 8:10AM $0.250 $0.175 fallen by 30%
$29 Annual Report to shareholders 30 Sep 2015 7:21PM $0.250 $0.175 fallen by 30%
$29 Appendix 3B - Release from escrow 30 Sep 2015 5:03PM $0.250 $0.175 fallen by 30%
$29 Entitlement Issue Prospectus Despatch 21 Sep 2015 4:35PM $0.220 $0.175 fallen by 20.45%
$29 Release from escrow 16 Sep 2015 5:52PM $0.270 $0.175 fallen by 35.19%
$29 Letter to Ineligible Shareholders - Entitlement Issue 15 Sep 2015 6:44PM $0.295 $0.175 fallen by 40.68%
$29 Letter to Eligible Shareholders - Entitlement Issue 15 Sep 2015 6:40PM $0.295 $0.175 fallen by 40.68%
$29 Non-renounceable Pro-rata Options Entitlement Issue 14 Sep 2015 9:59AM $0.310 $0.175 fallen by 43.55%
$29 Letter to option holders - Entitlement Issue 11 Sep 2015 6:15PM $0.310 $0.175 fallen by 43.55%
$29 Appendix 3B - Entitlement Issue 11 Sep 2015 6:12PM $0.310 $0.175 fallen by 43.55%
$29 Entitlement Issue Prospectus 11 Sep 2015 5:51PM $0.310 $0.175 fallen by 43.55%
$29 Investor Presentation - September 2015 2 Sep 2015 12:25PM $0.320 $0.175 fallen by 45.31%
$29 Preliminary Final Report 31 Aug 2015 1:58PM $0.360 $0.175 fallen by 51.39%
$29 Investor Presentation - August 2015 19 Aug 2015 10:22AM $0.360 $0.175 fallen by 51.39%
$29 Appendix 4C - June 2015 Quarterly Report 31 Jul 2015 6:07PM $0.340 $0.175 fallen by 48.53%
$29 Appendix 3B - Release from escrow 30 Jun 2015 6:07PM $0.345 $0.175 fallen by 49.28%
$29 Appendix 3B - Release from escrow 23 Jun 2015 6:38PM $0.440 $0.175 fallen by 60.23%
$29 Release from escrow 16 Jun 2015 6:02PM $0.485 $0.175 fallen by 63.92%
$29 Investor Presentation - June 2015 10 Jun 2015 10:27AM $0.590 $0.175 fallen by 70.34%
$29 Release from escrow 9 Jun 2015 6:19PM $0.710 $0.175 fallen by 75.35%
$29 Ground-breaking Predictive Test for Diabetic Kidney Disease 9 Jun 2015 8:28AM $0.205 $0.175 fallen by 14.63%
$29 Appendix 3B - Release from escrow 5 Jun 2015 4:13PM $0.205 $0.175 fallen by 14.63%
$29 Release from escrow 22 May 2015 6:25PM $0.205 $0.175 fallen by 14.63%
$29 Diagnostic Test Patent Accepted for Diabetic Kidney Disease 21 May 2015 9:34AM $0.205 $0.175 fallen by 14.63%

651 - 675 of 686 results

Page 27 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.